We are analyzing https://link.springer.com/article/10.1007/s12032-023-02201-8.

Title:
Unveiling the genetic and epigenetic landscape of colorectal cancer: new insights into pathogenic pathways | Medical Oncology
Description:
Colorectal cancer (CRC) is a complex disease characterized by genetic and epigenetic alterations, playing a crucial role in its development and progression. This review aims to provide insights into the emerging landscape of these alterations in CRC pathogenesis to develop effective diagnostic tools and targeted therapies. Genetic alterations in signaling pathways such as Wnt/β-catenin, and PI3K/Akt/mTOR are pivotal in CRC development. Genetic profiling has identified distinct molecular subtypes, enabling personalized treatment strategies. Epigenetic modifications, including DNA methylation and histone modifications, also contribute to CRC pathogenesis by influencing critical cellular processes through gene silencing or activation. Non-coding RNAs have emerged as essential players in epigenetic regulation and CRC progression. Recent research highlights the interplay between genetic and epigenetic alterations in CRC. Genetic mutations can affect epigenetic modifications, leading to dysregulated gene expression and signaling cascades. Conversely, epigenetic changes can modulate genetic expression, amplifying or dampening the effects of genetic alterations. Advancements in understanding pathogenic pathways have potential clinical applications. Identifying genetic and epigenetic markers as diagnostic and prognostic biomarkers promises more accurate risk assessment and early detection. Challenges remain, including validating biomarkers and developing robust therapeutic strategies through extensive research and clinical trials. The dynamic nature of genetic and epigenetic alterations necessitates a comprehensive understanding of their temporal and spatial patterns during CRC progression. In conclusion, the genetic and epigenetic landscape of CRC is increasingly being unraveled, providing valuable insights into its pathogenesis. Integrating genetic and epigenetic knowledge holds great potential for improving diagnostics, prognostics, and personalized therapies in CRC. Continued research efforts are vital to translate these findings into clinical practice, ultimately improving patient outcomes.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

pubmed, cancer, article, google, scholar, cas, central, colorectal, epigenetic, wang, mol, zhang, genetic, cell, signaling, therapy, therapeutic, cancers, mechanisms, dna, tumor, yang, httpsdoiorgs, review, alterations, molecular, sci, pathway, chen, pathways, biomarkers, liu, oncol, res, rev, int, targeting, potential, clinical, role, clin, progression, noncoding, colon, med, ther, methylation, regulation, epigenetics, target,

Topics {✒️}

mapk–ras–raf signaling pathway wnt/β-catenin signaling pathway pi3k/akt/mtor signaling pathway targeting wnt1/β-catenin pathway wnt/β-catenin pathway raf-mek-erk pathway pi3k/akt/mtor pathway pi3k-akt-mtor pathway month download article/chapter wnt/β-catenin signaling ras/mapk signaling pathway pi3k/akt/mtor pathways nf-κb signaling pathway mek/erk network wnt/β-catenin swi/snf complex offer pi3k/akt/mtor dna methylation-based diagnostic targeting aurka-cdc25c axis gastroenterol rev/przegląd gastroenterologiczny immune checkpoints pd-l1 noncoding rna-mediated mechanisms rna-binding proteins involved hippo–yap1 signaling pathways full article pdf immune‐related adverse events hippo signaling pathway braf-mutated colorectal cancer familial adenomatous polyposis npj precision oncology bmc med educ canonical wnt signaling dual proto-oncogene garcía-rodríguez jl receptor tyrosine kinases tgf-β signaling regulated cell death wnt pathway egfr-based targeted therapy privacy choices/manage cookies providing continuous support early-onset colorectal cancer related subjects tgf-β inhibitors check access instant access β-catenin noncoding cancer genome drug discovery today holds exclusive rights

Questions {❓}

Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?
Growth factors, PI3K/AKT/mTOR and MAPK Signaling pathways in colorectal cancer pathogenesis: where are we now?
PI3K/Akt/mTOR pathway and its role in cancer therapeutics: are we making headway?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Unveiling the genetic and epigenetic landscape of colorectal cancer: new insights into pathogenic pathways
         description:Colorectal cancer (CRC) is a complex disease characterized by genetic and epigenetic alterations, playing a crucial role in its development and progression. This review aims to provide insights into the emerging landscape of these alterations in CRC pathogenesis to develop effective diagnostic tools and targeted therapies. Genetic alterations in signaling pathways such as Wnt/β-catenin, and PI3K/Akt/mTOR are pivotal in CRC development. Genetic profiling has identified distinct molecular subtypes, enabling personalized treatment strategies. Epigenetic modifications, including DNA methylation and histone modifications, also contribute to CRC pathogenesis by influencing critical cellular processes through gene silencing or activation. Non-coding RNAs have emerged as essential players in epigenetic regulation and CRC progression. Recent research highlights the interplay between genetic and epigenetic alterations in CRC. Genetic mutations can affect epigenetic modifications, leading to dysregulated gene expression and signaling cascades. Conversely, epigenetic changes can modulate genetic expression, amplifying or dampening the effects of genetic alterations. Advancements in understanding pathogenic pathways have potential clinical applications. Identifying genetic and epigenetic markers as diagnostic and prognostic biomarkers promises more accurate risk assessment and early detection. Challenges remain, including validating biomarkers and developing robust therapeutic strategies through extensive research and clinical trials. The dynamic nature of genetic and epigenetic alterations necessitates a comprehensive understanding of their temporal and spatial patterns during CRC progression. In conclusion, the genetic and epigenetic landscape of CRC is increasingly being unraveled, providing valuable insights into its pathogenesis. Integrating genetic and epigenetic knowledge holds great potential for improving diagnostics, prognostics, and personalized therapies in CRC. Continued research efforts are vital to translate these findings into clinical practice, ultimately improving patient outcomes.
         datePublished:2023-10-19T00:00:00Z
         dateModified:2023-10-19T00:00:00Z
         pageStart:1
         pageEnd:28
         sameAs:https://doi.org/10.1007/s12032-023-02201-8
         keywords:
            Colorectal cancer
            Genetic alterations
            Epigenetic modifications
            Wnt
            β-catenin pathway
            PI3K
            Akt
            mTOR pathway
            Diagnostic biomarkers
            Precision medicine
            Oncology
            Hematology
            Pathology
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-023-02201-8/MediaObjects/12032_2023_2201_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-023-02201-8/MediaObjects/12032_2023_2201_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-023-02201-8/MediaObjects/12032_2023_2201_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-023-02201-8/MediaObjects/12032_2023_2201_Fig4_HTML.png
         isPartOf:
            name:Medical Oncology
            issn:
               1559-131X
            volumeNumber:40
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Humzah Postwala
               affiliation:
                     name:L. M. College of Pharmacy, Opp. Gujarat University
                     address:
                        name:Department of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, Opp. Gujarat University, Ahmedabad, India
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yesha Shah
               affiliation:
                     name:L. M. College of Pharmacy, Opp. Gujarat University
                     address:
                        name:Department of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, Opp. Gujarat University, Ahmedabad, India
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Priyajeet S. Parekh
               affiliation:
                     name:AV Pharma LLC
                     address:
                        name:AV Pharma LLC, Jacksonville, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mehul R. Chorawala
               url:http://orcid.org/0000-0002-3724-0986
               affiliation:
                     name:L. M. College of Pharmacy, Opp. Gujarat University
                     address:
                        name:Department of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, Opp. Gujarat University, Ahmedabad, India
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Unveiling the genetic and epigenetic landscape of colorectal cancer: new insights into pathogenic pathways
      description:Colorectal cancer (CRC) is a complex disease characterized by genetic and epigenetic alterations, playing a crucial role in its development and progression. This review aims to provide insights into the emerging landscape of these alterations in CRC pathogenesis to develop effective diagnostic tools and targeted therapies. Genetic alterations in signaling pathways such as Wnt/β-catenin, and PI3K/Akt/mTOR are pivotal in CRC development. Genetic profiling has identified distinct molecular subtypes, enabling personalized treatment strategies. Epigenetic modifications, including DNA methylation and histone modifications, also contribute to CRC pathogenesis by influencing critical cellular processes through gene silencing or activation. Non-coding RNAs have emerged as essential players in epigenetic regulation and CRC progression. Recent research highlights the interplay between genetic and epigenetic alterations in CRC. Genetic mutations can affect epigenetic modifications, leading to dysregulated gene expression and signaling cascades. Conversely, epigenetic changes can modulate genetic expression, amplifying or dampening the effects of genetic alterations. Advancements in understanding pathogenic pathways have potential clinical applications. Identifying genetic and epigenetic markers as diagnostic and prognostic biomarkers promises more accurate risk assessment and early detection. Challenges remain, including validating biomarkers and developing robust therapeutic strategies through extensive research and clinical trials. The dynamic nature of genetic and epigenetic alterations necessitates a comprehensive understanding of their temporal and spatial patterns during CRC progression. In conclusion, the genetic and epigenetic landscape of CRC is increasingly being unraveled, providing valuable insights into its pathogenesis. Integrating genetic and epigenetic knowledge holds great potential for improving diagnostics, prognostics, and personalized therapies in CRC. Continued research efforts are vital to translate these findings into clinical practice, ultimately improving patient outcomes.
      datePublished:2023-10-19T00:00:00Z
      dateModified:2023-10-19T00:00:00Z
      pageStart:1
      pageEnd:28
      sameAs:https://doi.org/10.1007/s12032-023-02201-8
      keywords:
         Colorectal cancer
         Genetic alterations
         Epigenetic modifications
         Wnt
         β-catenin pathway
         PI3K
         Akt
         mTOR pathway
         Diagnostic biomarkers
         Precision medicine
         Oncology
         Hematology
         Pathology
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-023-02201-8/MediaObjects/12032_2023_2201_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-023-02201-8/MediaObjects/12032_2023_2201_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-023-02201-8/MediaObjects/12032_2023_2201_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-023-02201-8/MediaObjects/12032_2023_2201_Fig4_HTML.png
      isPartOf:
         name:Medical Oncology
         issn:
            1559-131X
         volumeNumber:40
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Humzah Postwala
            affiliation:
                  name:L. M. College of Pharmacy, Opp. Gujarat University
                  address:
                     name:Department of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, Opp. Gujarat University, Ahmedabad, India
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yesha Shah
            affiliation:
                  name:L. M. College of Pharmacy, Opp. Gujarat University
                  address:
                     name:Department of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, Opp. Gujarat University, Ahmedabad, India
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Priyajeet S. Parekh
            affiliation:
                  name:AV Pharma LLC
                  address:
                     name:AV Pharma LLC, Jacksonville, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mehul R. Chorawala
            url:http://orcid.org/0000-0002-3724-0986
            affiliation:
                  name:L. M. College of Pharmacy, Opp. Gujarat University
                  address:
                     name:Department of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, Opp. Gujarat University, Ahmedabad, India
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Medical Oncology
      issn:
         1559-131X
      volumeNumber:40
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:L. M. College of Pharmacy, Opp. Gujarat University
      address:
         name:Department of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, Opp. Gujarat University, Ahmedabad, India
         type:PostalAddress
      name:L. M. College of Pharmacy, Opp. Gujarat University
      address:
         name:Department of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, Opp. Gujarat University, Ahmedabad, India
         type:PostalAddress
      name:AV Pharma LLC
      address:
         name:AV Pharma LLC, Jacksonville, USA
         type:PostalAddress
      name:L. M. College of Pharmacy, Opp. Gujarat University
      address:
         name:Department of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, Opp. Gujarat University, Ahmedabad, India
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Humzah Postwala
      affiliation:
            name:L. M. College of Pharmacy, Opp. Gujarat University
            address:
               name:Department of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, Opp. Gujarat University, Ahmedabad, India
               type:PostalAddress
            type:Organization
      name:Yesha Shah
      affiliation:
            name:L. M. College of Pharmacy, Opp. Gujarat University
            address:
               name:Department of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, Opp. Gujarat University, Ahmedabad, India
               type:PostalAddress
            type:Organization
      name:Priyajeet S. Parekh
      affiliation:
            name:AV Pharma LLC
            address:
               name:AV Pharma LLC, Jacksonville, USA
               type:PostalAddress
            type:Organization
      name:Mehul R. Chorawala
      url:http://orcid.org/0000-0002-3724-0986
      affiliation:
            name:L. M. College of Pharmacy, Opp. Gujarat University
            address:
               name:Department of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, Opp. Gujarat University, Ahmedabad, India
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, Opp. Gujarat University, Ahmedabad, India
      name:Department of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, Opp. Gujarat University, Ahmedabad, India
      name:AV Pharma LLC, Jacksonville, USA
      name:Department of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, Opp. Gujarat University, Ahmedabad, India
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(803)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.87s.

LINK . SPRINGER . COM {}